Pharmaceutical intermediates are actually some chemical raw materials or chemical products used in the process of pharmaceutical synthesis. This chemical, which does not require a drug production license, can be produced in ordinary chemical plants and can be used in the synthesis of drugs as long as it reaches certain grades.
Analysis of Pharmaceutical intermediates industry in China
Champ consulting industry analysts pointed out that China needs about 2000 kinds of raw materials and intermediates for chemical industry every year, and the demand is more than 2.5 million tons. After more than 30 years of development, China's pharmaceutical production of chemical raw materials and intermediates can be basically matching, only a small part of the need to import. Moreover, due to abundant resources and low raw material prices in China, many intermediates have been exported in large quantities.
Looking at the whole industry, China's current pharmaceutical intermediates production has six characteristics:
First, most of the production enterprises are private enterprises with flexible operation and small scale of investment, basically between millions and one or two million yuan.
Second, the regional distribution of production enterprises is relatively concentrated, mainly distributed in taizhou, Zhejiang and Jintan, Jiangsu as the center of the region.
Third, with the increasing attention of the state to environmental protection issues, the pressure on production enterprises to build environmental protection treatment facilities increases.
Fourth, product update speed is fast. After a product is put on the market for 3 to 5 years, its profit margin will drop significantly, which forces the enterprise to develop new products or improve the production process constantly, in order to maintain a high production profit.
Fifth, because the production profit of pharmaceutical intermediates is higher than that of chemical products, and the production process of the two is basically the same, more and more small chemical enterprises join in the production of pharmaceutical intermediates, leading to increasingly fierce disordered competition in the industry.
Sixth, compared with API, the profit margin of manufacturing intermediates is low, and the production process of API and pharmaceutical intermediates is similar. Therefore, some enterprises have not only produced intermediates, but also started to produce API by taking advantage of their own advantages.
In China's pharmaceutical intermediates product chain, intermediate products of medium and upstream basic API occupy a dominant position in the whole chain due to their wide application fields, so they have developed rapidly and attracted much attention in the market.
However, China's export of pharmaceutical intermediates has also come under pressure from other countries, especially India. India's rapid rise in the pharmaceutical industry now has a competitive and symbiotic relationship with China. Facts have proved that the impact from India cannot be ignored in the main export areas of pharmaceutical intermediates in China, such as the European Union, North America, the Middle East and Southeast Asia.
Champ consulting released "2014-2017 China pharmaceutical intermediates market analysis depth research report shows that China's pharmaceutical intermediates industry itself also exist such as the low value-added products, the lack of independent intellectual property products, export channels and information support is insufficient, inadequate information resource utilization and so on aspects of the" short board ", plus water and electricity coal transport and chemical raw materials prices, the rising cost of environmental protection, and part of the medical commodity export tax rebates and other external cause, competitive threats to its international market advantage.